A Phase 3 interventional study of OPC-34712 + ADT and Placebo + ADT in Depressive Disorder, Depression and Depressive Disorder, Major, sponsored by Otsuka Pharmaceutical Development & Commercialization, Inc.. Completed at 57 sites in 5 countries. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2015-11-26.
Sponsored by Otsuka Pharmaceutical Development & Commercialization, Inc. (part of Otsuka Holdings Co., Ltd.) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 24 studies testing brexpiprazole in Depressive Disorder, Major — 1 open to participants now, 1 under way, none of them phase 3. brexpiprazole · Depressive Disorder, Major.
Among the 24 studies testing brexpiprazole in Depressive Disorder, Major, this one is the 8th largest by enrollment, is one of 2 that started in 2011, is one of 16 in phase 3, and was the 3rd registered.
3,050 studies on the registry are indexed under Depressive Disorder, Major; 594 are open to participants now.
Browse Depressive Disorder, Major studies →1 of the 24 studies testing brexpiprazole in Depressive Disorder, Major is open now, in 1 country. Recruiting first, the newest first:
Nova Scotia Health Authority · Sites in Canada
Ages 18–65 · Healthy volunteers
By country, each count listing its studies:
brexpiprazole: first FDA approval 2015 (REXULTI), first EMA approval 2018. What it is approved for, and how studies give it, is on its page →
Of the 417 Depressive Disorder, Major studies recruiting now, 93 (22%) set no upper age limit and 297 (71%) stop at 75 or younger; 55 take children under 18; 100 take healthy volunteers.
This study: 18 Years to 65 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
24 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 1 · Phase 2 4 · Phase 3 17 · Phase 4 3
First in 2009; this study’s year is marked. 2 started in 2011.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 826 is above the median of 79 across 2,535 interventional studies indexed under Depressive Disorder, Major.
Median enrollment 189 across the 24 interventional studies. Of the 21 that completed or were terminated, 19 (90%) have results posted.
This tab as a report to print or save as PDF → With an account.
22 of 24 have an industry lead sponsor. The 6 most frequent:
This study is registered under Otsuka Pharmaceutical Development & Commercialization, Inc., one of the names counted as Otsuka Holdings Co., Ltd.. Under that name alone:
Otsuka Pharmaceutical Development & Commercialization, Inc. is the lead sponsor of 297 studies on the registry; 19 are open to participants now.
Of its 106 completed or terminated interventional studies of FDA-regulated products, 71 (67%) have results posted.
45 studies in Depressive Disorder, Major by Otsuka Holdings Co., Ltd.: none open now, none under way, none of them phase 3. Of 42 finished, 29 (69%) have results posted.
Among the 45 studies in Depressive Disorder, Major by Otsuka Holdings Co., Ltd., this one is the 12th largest by enrollment of the 40 interventional ones that give a count, is one of 5 that started in 2011, is one of 23 in phase 3, and was the 17th registered.
Otsuka Holdings Co., Ltd.’s Depressive Disorder, Major studies by the year they started, since 2004.
None of the studies under way reaches primary completion within a year.
Among the 24 studies testing brexpiprazole in Depressive Disorder, Major, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Otsuka Holdings Co., Ltd.’s 45 in Depressive Disorder, Major:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
To compare the effect of OPC-34712 (brexpiprazole) to the effect of placebo (an inactive substance) as add on treatment to an assigned FDA approved antidepressant treatment (ADT) in patients with Major Depressive Disorder who demonstrate an incomplete response to a prospective trial of the same assigned FDA approved ADT
3,050 studies on the registry are indexed under Depressive Disorder, Major; 594 are open to participants now.
This study's enrollment of 826 is above the median of 79 across 2,535 interventional studies indexed under Depressive Disorder, Major.
Browse Depressive Disorder, Major studies →Otsuka Pharmaceutical Development & Commercialization, Inc. is the lead sponsor of 297 studies on the registry; 19 are open to participants now.
Of its 106 completed or terminated interventional studies of FDA-regulated products, 71 (67%) have results posted.
Compared within Depressive Disorder, Major, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Depressive Disorder. The counts are of registry records indexed under each term, refreshed daily. How we classify →
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
DSM diagnostic criteria
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: OPC-34712 + ADT Drug: Placebo + ADT
Drug: OPC-34712 + ADT · Drug: Placebo + ADT
Intervention: Drug: Placebo + ADT
Drug: Placebo + ADT
Drug pages: BrexpiprazoleStudies of BrexpiprazoleBrexpiprazole pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record. · AntiandrogensStudies of AntiandrogensAntiandrogens pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.
Tablet, Oral, 2 mg OPC-34712 and FDA Approved Antidepressant Therapy (ADT)
Placebo + FDA Approved Antidepressant (ADT)
Placebo + FDA Approved Antidepressant (ADT)
Change From Baseline (End of Phase A [Week 8]) to Week 14 in Montgomery-Asberg Depression Rating Scale (MADRS) Total Score for the Efficacy Sample.
The MADRS consists of 10 items, all rated on a 0 to 6 scale with 0 being the "best" rating and 6 being the "worst" rating. The MADRS total score is the sum of ratings for all 10 items. The possible total scores are from 0 to 60. The MADRS total score will be un-evaluable if less than 8 of the 10 items are recorded. If 8 or 9 of the 10 items are recorded, the MADRS total score will be the mean of the recorded items multiplied by 10 and then rounded to the first decimal place.
Time frame: Baseline and Week 14
Change From Baseline (End of Phase A [Week 8]) to Week 14 in MADRS Total Score for the Efficacy Sample Per the Final Protocol.
The MADRS consists of 10 items, all rated on a 0 to 6 scale with 0 being the "best" rating and 6 being the "worst" rating. The MADRS total score is the sum of ratings for all 10 items. The possible total scores are from 0 to 60. The MADRS total score will be un-evaluable if less than 8 of the 10 items are recorded. If 8 or 9 of the 10 items are recorded, the MADRS total score will be the mean of the recorded items multiplied by 10 and then rounded to the first decimal place.
Time frame: Baseline and Week 14
Mean Change From Baseline (End of Phase A [Week 8]) to Week 14 in Sheehan Disability Scale (SDS) Score for the Efficacy Sample.
The SDS is a self-rated instrument used to measure the effect of the patient's symptoms on work/school, social life, and family/home responsibilities. For each of the three items, scores range from 0 through 10. The number most representative of how much each area was disrupted by symptoms is marked along the line from 0 = not at all, to 10 = extremely. For the work/school item, no response was to be entered if the patient did not work or go to school for reasons unrelated to the disorder and a response therefore not being applicable. The Mean SDS Score will be calculated over the three item scores. All three item scores need to be available with the exception of the work/school item score when this item is not applicable.
Time frame: Baseline and Week 14
Mean Change From Baseline (End of Phase A [Week 8]) to Week 14 in SDS Score for the Efficacy Sample Per the Final Protocol
The SDS is a self-rated instrument used to measure the effect of the patient's symptoms on work/school, social life, and family/home responsibilities. For each of the three items, scores range from 0 through 10. The number most representative of how much each area was disrupted by symptoms is marked along the line from 0 = not at all, to 10 = extremely. For the work/school item, no response was to be entered if the patient did not work or go to school for reasons unrelated to the disorder and a response therefore not being applicable. The Mean SDS Score will be calculated over the three item scores. All three item scores need to be available with the exception of the work/school item score when this item is not applicable.
Time frame: Baseline and Week 14
Change From Baseline (End of Phase A [Week 8]) to Week 14 in MADRS Total Score by Trial Week for the Efficacy Sample.
The MADRS consists of 10 items, all rated on a 0 to 6 scale with 0 being the "best" rating and 6 being the "worst" rating. The MADRS total score is the sum of ratings for all 10 items. The possible total scores are from 0 to 60. The MADRS total score will be un-evaluable if less than 8 of the 10 items are recorded. If 8 or 9 of the 10 items are recorded, the MADRS total score will be the mean of the recorded items multiplied by 10 and then rounded to the first decimal place.
Time frame: Week 9, 10, 11, 12, and 13
Change From Baseline (End of Phase A [Week 8]) to Week 14 in MADRS Total Score by Trial Week for the Efficacy Sample Per the Final Protocol.
The MADRS consists of 10 items, all rated on a 0 to 6 scale with 0 being the "best" rating and 6 being the "worst" rating. The MADRS total score is the sum of ratings for all 10 items. The possible total scores are from 0 to 60. The MADRS total score will be un-evaluable if less than 8 of the 10 items are recorded. If 8 or 9 of the 10 items are recorded, the MADRS total score will be the mean of the recorded items multiplied by 10 and then rounded to the first decimal place.
Time frame: Week 9, 10, 11, 12, and 13
Mean Clinical Global Impression-Improvement (CGI-I) Scale Score (End of Phase A [Week 8]) to Week 14 by Trial Week for the Efficacy Sample.
The items on CGI-I scale are: 0 = not assessed, 1 = very much improved, 2 = much improved, 3 = minimally improved, 4 = no change, 5 = minimally worse, 6 = much worse, 7 = very much worse. The score of 0 (= not assessed) will be set to missing. The CGI-I is therefore a 7-point scale from 1 through 7. The CGI-I was measured in related to Baseline (Week 8).
Time frame: Week 9, 10, 11, 12, 13, and 14
Mean CGI-I Scale Score (End of Phase A [Week 8]) to Week 14 by Trial Week for the Efficacy Sample Per the Final Protocol.
The items on CGI-I scale are: 0 = not assessed, 1 = very much improved, 2 = much improved, 3 = minimally improved, 4 = no change, 5 = minimally worse, 6 = much worse, 7 = very much worse. The score of 0 (= not assessed) will be set to missing. The CGI-I is therefore a 7-point scale from 1 through 7. The CGI-I was measured in related to Baseline (Week 8).
Time frame: Week 9, 10, 11, 12, 13, and 14
Change From Baseline (End of Phase A [Week 8]) to Week 14 in Clinical Global Impression - Severity of Illness (CGI-S) Scale Score for the Efficacy Sample.
Items on CGI-S scale are: 0 = not assessed, 1 = normal, not at all ill, 2 = borderline mentally ill, 3 = mildly ill, 4 = moderately ill, 5 = markedly ill, 6 = severely ill, 7 = among the most extremely ill patients. The score 0 (= not assessed) will be set to missing. The CGI-S is therefore a 7-point scale from 1 through 7.
Time frame: Week 9, 10, 11, 12, 13, and 14
Change From Baseline (End of Phase A [Week 8]) to Week 14 in CGI-S Scale Score for the Efficacy Sample Per the Final Protocol.
Items on CGI-S scale are: 0 = not assessed, 1 = normal, not at all ill, 2 = borderline mentally ill, 3 = mildly ill, 4 = moderately ill, 5 = markedly ill, 6 = severely ill, 7 = among the most extremely ill patients. The score 0 (= not assessed) will be set to missing. The CGI-S is therefore a 7-point scale from 1 through 7.
Time frame: Week 9, 10, 11, 12, 13, and 14
Change From Baseline (End of Phase A [Week 8]) to Week 14 in the Inventory of Depressive Symptomatology (Self-Report) (IDS-SR) Total Score for the Efficacy Sample.
The IDS-SR consists of 30 items, all rated on a 0 to 3 scale with 0 being the "best" rating and 3 being the "worst" rating. Besides item 9, two sub-items 9A and 9B exist, with possible scores of 1, 2 or 3 for item 9A, and 0 or 1 for item 9B. The scores for these two sub-items are not included in the calculation of the total score. Item 11 or item 12 should be completed but not both, and similarly, item 13 or item 14 should be completed but not both. Should items 11 and 12 be rated both, then the maximum of the two scores will be used. The same approach will be used for handling items 13 and 14. The IDS-SR total score is the sum of ratings of 28 item scores. The possible IDS-SR total score ranges from 0 to 84.
Time frame: Week 9, 10, 11, 12, 13, and 14
Change From Baseline (End of Phase A [Week 8]) to Week 14 in the IDS-SR Total Score for the Efficacy Sample Per the Final Protocol.
The IDS-SR consists of 30 items, all rated on a 0 to 3 scale with 0 being the "best" rating and 3 being the "worst" rating. Besides item 9, two sub-items 9A and 9B exist, with possible scores of 1, 2 or 3 for item 9A, and 0 or 1 for item 9B. The scores for these two sub-items are not included in the calculation of the total score. Item 11 or item 12 should be completed but not both, and similarly, item 13 or item 14 should be completed but not both. Should items 11 and 12 be rated both, then the maximum of the two scores will be used. The same approach will be used for handling items 13 and 14. The IDS-SR total score is the sum of ratings of 28 item scores. The possible IDS-SR total score ranges from 0 to 84.
Time frame: Week 9, 10, 11, 12, 13, and 14
Change From Baseline (End of Phase A [Week 8]) in SDS Item Scores for the Efficacy Sample.
The SDS is a self-rated instrument used to measure the effect of the patient's symptoms on work/school, social life, and family/home responsibilities. For each of the three items, scores range from 0 through 10. The number most representative of how much each area was disrupted by symptoms is marked along the line from 0 = not at all, to 10 = extremely. For the work/school item, no response was to be entered if the patient did not work or go to school for reasons unrelated to the disorder and a response therefore not being applicable. The Mean SDS Score will be calculated over the three item scores. All three item scores need to be available with the exception of the work/school item score when this item is not applicable.
Time frame: Week 11 and 14
Change From Baseline (End of Phase A [Week 8]) in SDS Item Scores for the Efficacy Sample Per the Final Protocol.
The SDS is a self-rated instrument used to measure the effect of the patient's symptoms on work/school, social life, and family/home responsibilities. For each of the three items, scores range from 0 through 10. The number most representative of how much each area was disrupted by symptoms is marked along the line from 0 = not at all, to 10 = extremely. For the work/school item, no response was to be entered if the patient did not work or go to school for reasons unrelated to the disorder and a response therefore not being applicable. The Mean SDS Score will be calculated over the three item scores. All three item scores need to be available with the exception of the work/school item score when this item is not applicable.
Time frame: Week 11 and 14
Change From Baseline (End of Phase A [Week 8]) to Week 14 in Hamilton Depression (HAM-D) Rating Scale Total Score for the Efficacy Sample.
The HAM-D (17-Item) consists of 17 items. Eight items are rated on a 0 to 2 scale (items 4, 5, 6, 12, 13, 14, 16 and 17), while nine items (items 1, 2, 3, 7, 8, 9, 10, 11, and 15) are rated on a 0 to 4 scale (twice the weight of the other items). For all of these items, 0 is the "best" rating and the highest score (2 or 4) is the "worst" rating. The sum of the scores from the first 17 items; 0-7 =Normal; 8-13 =mild depression; 14-18 =moderate depression; 19-22 =severe depression; ≥23 =very severe depression. The total score ranges from 0 to 52, with higher score indicating worse depressive symptoms.
Time frame: Baseline and Week 14
Change From Baseline (End of Phase A [Week 8]) to Week 14 in HAM-D Rating Scale Total Score for the Efficacy Sample Per the Final Protocol.
The HAM-D (17-Item) consists of 17 items. Eight items are rated on a 0 to 2 scale (items 4, 5, 6, 12, 13, 14, 16 and 17), while nine items (items 1, 2, 3, 7, 8, 9, 10, 11, and 15) are rated on a 0 to 4 scale (twice the weight of the other items). For all of these items, 0 is the "best" rating and the highest score (2 or 4) is the "worst" rating. The sum of the scores from the first 17 items; 0-7 =Normal; 8-13 =mild depression; 14-18 =moderate depression; 19-22 =severe depression; ≥23 =very severe depression. The total score ranges from 0 to 52, with higher score indicating worse depressive symptoms.
Time frame: Baseline and Week 14
Change From Baseline (End of Phase A [Week 8]) to Week 14 in Hamilton Anxiety (HAM-A) Rating Scale Total Score for the Efficacy Sample
The HAM-A is utilized for the evaluation of anxiety symptoms. The HAM-A consists of 14 items. Each item is rated on a 0 to 4 scale. For all of these items, 0 is the "best" rating and 4 is the "worst" rating. If no item scores are missing, then the HAM-A total score is the sum of all 14 item scores. The possible total scores are from 0 to 56, with higher scores indicating worse anxiety symptoms.
Time frame: Baseline and Week 14
Change From Baseline (End of Phase A [Week 8]) to Week 14 in HAM-A Rating Scale Total Score for the Efficacy Sample Per the Final Protocol.
The HAM-A is utilized for the evaluation of anxiety symptoms. The HAM-A consists of 14 items. Each item is rated on a 0 to 4 scale. For all of these items, 0 is the "best" rating and 4 is the "worst" rating. If no item scores are missing, then the HAM-A total score is the sum of all 14 item scores. The possible total scores are from 0 to 56, with higher scores indicating worse anxiety symptoms.
Time frame: Baseline and Week 14
Percentage of Participants With MADRS Response at Week 14 Relative to Baseline (End of Phase A [Week 8]) for the Efficacy Sample.
The MADRS response was defined as \>/=50% reduction in MADRS total score from end of Phase A (Week 8).
Time frame: Baseline and Week 14
Percentage of Participants With MADRS Response at Week 14 Relative to Baseline (End of Phase A [Week 8]) for the Efficacy Sample Per the Final Protocol.
The MADRS response was defined as \>/=50% reduction in MADRS total score from end of Phase A (Week 8).
Time frame: Baseline and Week 14
Percentage of Participants With MADRS Remission at Week 14 Relative to Baseline (End of Phase A [Week 8]) for the Efficacy Sample.
MADRS remission was defined as \</=10 and \>/=50% reduction in MADRS total score from end of Phase A (Week 8).
Time frame: Baseline and Week 14
Percentage of Participants With MADRS Remission at Week 14 Relative to Baseline (End of Phase A [Week 8]) for the Efficacy Sample Per the Final Protocol.
MADRS remission was defined as \</=10 and \>/=50% reduction in MADRS total score from end of Phase A (Week 8).
Time frame: Baseline and Week 14
Percentage of Participants With CGI-I Scale Response Rate at Week 14 Relative to Baseline (End of Phase A [Week 8]) for the Efficacy Sample.
CGI-I response was defined as a CGI-I score of 1 (very much improved) or 2 (much improved).
Time frame: Baseline and Week 14
Percentage of Participants With CGI-I Scale Response Rate at Week 14 Relative to Baseline (End of Phase A [Week 8]) for the Efficacy Sample Per the Final Protocol.
CGI-I response was defined as a CGI-I score of 1 (very much improved) or 2 (much improved).
Time frame: Baseline and Week 14
This trial was conducted in 826 subjects at 59 trial sites in the following 5 countries: United States, Canada, Poland, Slovakia, and France.
| Milestone | Single-blind Placebo + ADT | Brexpiprazole 2 mg/Day + ADT | Double-blind Placebo + ADT | Phase A+ Placebo + ADT |
|---|---|---|---|---|
| Started | 824 | 0 | 0 | 0 |
| Completed | 710 | 0 | 0 | 0 |
| Not completed | 114 | 0 | 0 | 0 |
| Withdrew: Lost to follow-up | 16 | 0 | 0 | 0 |
| Withdrew: Adverse event | 19 | 0 | 0 | 0 |
| Withdrew: Met withdrawal criteria | 16 | 0 | 0 | 0 |
| Withdrew: Withdrawal by subject | 34 | 0 | 0 | 0 |
| Withdrew: Protocol deviation | 24 | 0 | 0 | 0 |
| Withdrew: Physician decision | 5 | 0 | 0 | 0 |
| Milestone | Single-blind Placebo + ADT | Brexpiprazole 2 mg/Day + ADT | Double-blind Placebo + ADT | Phase A+ Placebo + ADT |
|---|---|---|---|---|
| Started | 0 | 188 | 191 | 0 |
| Completed | 0 | 174 | 178 | 0 |
| Not completed | 0 | 14 | 13 | 0 |
| Withdrew: Lost to follow-up | 0 | 1 | 0 | 0 |
| Withdrew: Adverse event | 0 | 6 | 0 | 0 |
| Withdrew: Met withdrawal criteria | 0 | 3 | 2 | 0 |
| Withdrew: Withdrawal by subject | 0 | 3 | 8 | 0 |
| Withdrew: Protocol deviation | 0 | 1 | 3 | 0 |
| Milestone | Single-blind Placebo + ADT | Brexpiprazole 2 mg/Day + ADT | Double-blind Placebo + ADT | Phase A+ Placebo + ADT |
|---|---|---|---|---|
| Started | 0 | 0 | 0 | 331 |
| Completed | 0 | 0 | 0 | 307 |
| Not completed | 0 | 0 | 0 | 24 |
| Withdrew: Lost to follow-up | 0 | 0 | 0 | 7 |
| Withdrew: Adverse event | 0 | 0 | 0 | 2 |
| Withdrew: Met withdrawal criteria | 0 | 0 | 0 | 4 |
| Withdrew: Physician decision | 0 | 0 | 0 | 2 |
| Withdrew: Withdrawal by subject | 0 | 0 | 0 | 5 |
| Withdrew: Protocol deviation | 0 | 0 | 0 | 4 |
The MADRS consists of 10 items, all rated on a 0 to 6 scale with 0 being the "best" rating and 6 being the "worst" rating. The MADRS total score is the sum of ratings for all 10 items. The possible total scores are from 0 to 60. The MADRS total score will be un-evaluable if less than 8 of the 10 items are recorded. If 8 or 9 of the 10 items are recorded, the MADRS total score will be the mean of the recorded items multiplied by 10 and then rounded to the first decimal place.
| Units on a scale | Brexpiprazole 2 mg/Day + ADT | Double-blind Placebo + ADT |
|---|---|---|
| Change From Baseline (End of Phase A [Week 8]) to Week 14 in Montgomery-Asberg Depression Rating Scale (MADRS) Total Score for the Efficacy Sample. | -8.27 ± 0.61 | -5.15 ± 0.60 |
The MADRS consists of 10 items, all rated on a 0 to 6 scale with 0 being the "best" rating and 6 being the "worst" rating. The MADRS total score is the sum of ratings for all 10 items. The possible total scores are from 0 to 60. The MADRS total score will be un-evaluable if less than 8 of the 10 items are recorded. If 8 or 9 of the 10 items are recorded, the MADRS total score will be the mean of the recorded items multiplied by 10 and then rounded to the first decimal place.
| Units on a scale | Brexpiprazole 2 mg/Day + ADT | Double-blind Placebo + ADT |
|---|---|---|
| Change From Baseline (End of Phase A [Week 8]) to Week 14 in MADRS Total Score for the Efficacy Sample Per the Final Protocol. | -8.36 ± 0.64 | -5.15 ± 0.63 |
The SDS is a self-rated instrument used to measure the effect of the patient's symptoms on work/school, social life, and family/home responsibilities. For each of the three items, scores range from 0 through 10. The number most representative of how much each area was disrupted by symptoms is marked along the line from 0 = not at all, to 10 = extremely. For the work/school item, no response was to be entered if the patient did not work or go to school for reasons unrelated to the disorder and a response therefore not being applicable. The Mean SDS Score will be calculated over the three item scores. All three item scores need to be available with the exception of the work/school item score when this item is not applicable.
| Units on a scale | Brexpiprazole 2 mg/Day + ADT | Double-blind Placebo + ADT |
|---|---|---|
| Mean Change From Baseline (End of Phase A [Week 8]) to Week 14 in Sheehan Disability Scale (SDS) Score for the Efficacy Sample. | -1.35 ± 0.17 | -0.91 ± 0.17 |
The SDS is a self-rated instrument used to measure the effect of the patient's symptoms on work/school, social life, and family/home responsibilities. For each of the three items, scores range from 0 through 10. The number most representative of how much each area was disrupted by symptoms is marked along the line from 0 = not at all, to 10 = extremely. For the work/school item, no response was to be entered if the patient did not work or go to school for reasons unrelated to the disorder and a response therefore not being applicable. The Mean SDS Score will be calculated over the three item scores. All three item scores need to be available with the exception of the work/school item score when this item is not applicable.
| Units on a scale | Brexpiprazole 2 mg/Day + ADT | Double-blind Placebo + ADT |
|---|---|---|
| Mean Change From Baseline (End of Phase A [Week 8]) to Week 14 in SDS Score for the Efficacy Sample Per the Final Protocol | -1.35 ± 0.17 | -0.89 ± 0.17 |
The MADRS consists of 10 items, all rated on a 0 to 6 scale with 0 being the "best" rating and 6 being the "worst" rating. The MADRS total score is the sum of ratings for all 10 items. The possible total scores are from 0 to 60. The MADRS total score will be un-evaluable if less than 8 of the 10 items are recorded. If 8 or 9 of the 10 items are recorded, the MADRS total score will be the mean of the recorded items multiplied by 10 and then rounded to the first decimal place.
| Units on a scale | Brexpiprazole 2 mg/Day + ADT | Double-blind Placebo + ADT |
|---|---|---|
| Week 9 | -3.15 ± 0.40 | -1.86 ± 0.39 |
| Week 10 | -5.15 ± 0.47 | -3.43 ± 0.47 |
| Week 11 | -6.69 ± 0.52 | -4.06 ± 0.52 |
| Week 12 | -7.22 ± 0.55 | -4.63 ± 0.54 |
| Week 13 | -8.28 ± 0.58 | -5.10 ± 0.57 |
The MADRS consists of 10 items, all rated on a 0 to 6 scale with 0 being the "best" rating and 6 being the "worst" rating. The MADRS total score is the sum of ratings for all 10 items. The possible total scores are from 0 to 60. The MADRS total score will be un-evaluable if less than 8 of the 10 items are recorded. If 8 or 9 of the 10 items are recorded, the MADRS total score will be the mean of the recorded items multiplied by 10 and then rounded to the first decimal place.
| Units on a scale | Brexpiprazole 2 mg/Day + ADT | Double-blind Placebo + ADT |
|---|---|---|
| Week 9 | -3.05 ± 0.41 | -1.74 ± 0.41 |
| Week 10 | -5.04 ± 0.49 | -3.52 ± 0.48 |
| Week 11 | -6.58 ± 0.54 | -4.17 ± 0.53 |
| Week 12 | -7.24 ± 0.58 | -4.72 ± 0.57 |
| Week 13 | -8.28 ± 0.61 | -5.01 ± 0.60 |
The items on CGI-I scale are: 0 = not assessed, 1 = very much improved, 2 = much improved, 3 = minimally improved, 4 = no change, 5 = minimally worse, 6 = much worse, 7 = very much worse. The score of 0 (= not assessed) will be set to missing. The CGI-I is therefore a 7-point scale from 1 through 7. The CGI-I was measured in related to Baseline (Week 8).
| Units on a scale | Brexpiprazole 2 mg/Day + ADT | Double-blind Placebo + ADT |
|---|---|---|
| Week 9 | 3.41 ± 0.83 | 3.62 ± 0.74 |
| Week 10 | 3.17 ± 0.89 | 3.37 ± 0.82 |
| Week 11 | 3.03 ± 1.02 | 3.23 ± 0.90 |
| Week 12 | 2.84 ± 0.99 | 3.19 ± 1.04 |
| Week 13 | 2.74 ± 1.07 | 3.13 ± 1.06 |
| Week 14 | 2.75 ± 1.13 | 3.13 ± 1.09 |
The items on CGI-I scale are: 0 = not assessed, 1 = very much improved, 2 = much improved, 3 = minimally improved, 4 = no change, 5 = minimally worse, 6 = much worse, 7 = very much worse. The score of 0 (= not assessed) will be set to missing. The CGI-I is therefore a 7-point scale from 1 through 7. The CGI-I was measured in related to Baseline (Week 8).
| Units on a scale | Brexpiprazole 2 mg/Day + ADT | Double-blind Placebo + ADT |
|---|---|---|
| Week 9 | 3.44 ± 0.81 | 3.67 ± 0.70 |
| Week 10 | 3.21 ± 0.89 | 3.40 ± 0.82 |
| Week 11 | 3.07 ± 1.01 | 3.25 ± 0.89 |
| Week 12 | 2.85 ± 1.01 | 3.23 ± 1.05 |
| Week 13 | 2.78 ± 1.07 | 3.18 ± 1.06 |
| Week 14 | 2.77 ± 1.14 | 3.17 ± 1.10 |
Items on CGI-S scale are: 0 = not assessed, 1 = normal, not at all ill, 2 = borderline mentally ill, 3 = mildly ill, 4 = moderately ill, 5 = markedly ill, 6 = severely ill, 7 = among the most extremely ill patients. The score 0 (= not assessed) will be set to missing. The CGI-S is therefore a 7-point scale from 1 through 7.
| Units on a scale | Brexpiprazole 2 mg/Day + ADT | Double-blind Placebo + ADT |
|---|---|---|
| Week 9 | -0.25 ± 0.05 | -0.12 ± 0.05 |
| Week 10 | -0.45 ± 0.05 | -0.31 ± 0.05 |
| Week 11 | -0.61 ± 0.06 | -0.40 ± 0.06 |
| Week 12 | -0.70 ± 0.07 | -0.45 ± 0.06 |
| Week 13 | -0.86 ± 0.07 | -0.50 ± 0.07 |
| Week 14 | -0.91 ± 0.07 | -0.58 ± 0.07 |
Items on CGI-S scale are: 0 = not assessed, 1 = normal, not at all ill, 2 = borderline mentally ill, 3 = mildly ill, 4 = moderately ill, 5 = markedly ill, 6 = severely ill, 7 = among the most extremely ill patients. The score 0 (= not assessed) will be set to missing. The CGI-S is therefore a 7-point scale from 1 through 7.
| Units on a scale | Brexpiprazole 2 mg/Day + ADT | Double-blind Placebo + ADT |
|---|---|---|
| Week 9 | -0.24 ± 0.05 | -0.09 ± 0.05 |
| Week 10 | -0.43 ± 0.06 | -0.32 ± 0.06 |
| Week 11 | -0.58 ± 0.06 | -0.42 ± 0.06 |
| Week 12 | -0.70 ± 0.07 | -0.46 ± 0.07 |
| Week 13 | -0.85 ± 0.07 | -0.50 ± 0.07 |
| Week 14 | -0.91 ± 0.07 | -0.57 ± 0.07 |
The IDS-SR consists of 30 items, all rated on a 0 to 3 scale with 0 being the "best" rating and 3 being the "worst" rating. Besides item 9, two sub-items 9A and 9B exist, with possible scores of 1, 2 or 3 for item 9A, and 0 or 1 for item 9B. The scores for these two sub-items are not included in the calculation of the total score. Item 11 or item 12 should be completed but not both, and similarly, item 13 or item 14 should be completed but not both. Should items 11 and 12 be rated both, then the maximum of the two scores will be used. The same approach will be used for handling items 13 and 14. The IDS-SR total score is the sum of ratings of 28 item scores. The possible IDS-SR total score ranges from 0 to 84.
| Units on a scale | Brexpiprazole 2 mg/Day + ADT | Double-blind Placebo + ADT |
|---|---|---|
| Week 9 | -3.02 ± 0.52 | -1.45 ± 0.51 |
| Week 10 | -4.17 ± 0.59 | -2.64 ± 0.59 |
| Week 11 | -5.41 ± 0.65 | -4.31 ± 0.64 |
| Week 12 | -6.16 ± 0.68 | -4.69 ± 0.67 |
| Week 13 | -7.00 ± 0.72 | -5.25 ± 0.71 |
| Week 14 | -7.49 ± 0.74 | -5.52 ± 0.73 |
The IDS-SR consists of 30 items, all rated on a 0 to 3 scale with 0 being the "best" rating and 3 being the "worst" rating. Besides item 9, two sub-items 9A and 9B exist, with possible scores of 1, 2 or 3 for item 9A, and 0 or 1 for item 9B. The scores for these two sub-items are not included in the calculation of the total score. Item 11 or item 12 should be completed but not both, and similarly, item 13 or item 14 should be completed but not both. Should items 11 and 12 be rated both, then the maximum of the two scores will be used. The same approach will be used for handling items 13 and 14. The IDS-SR total score is the sum of ratings of 28 item scores. The possible IDS-SR total score ranges from 0 to 84.
| Units on a scale | Brexpiprazole 2 mg/Day + ADT | Double-blind Placebo + ADT |
|---|---|---|
| Week 9 | -3.30 ± 0.53 | -1.59 ± 0.51 |
| Week 10 | -4.29 ± 0.61 | -3.13 ± 0.60 |
| Week 11 | -5.45 ± 0.67 | -4.73 ± 0.66 |
| Week 12 | -6.32 ± 0.71 | -5.06 ± 0.70 |
| Week 13 | -7.03 ± 0.74 | -5.60 ± 0.73 |
| Week 14 | -7.59 ± 0.77 | -6.05 ± 0.75 |
The SDS is a self-rated instrument used to measure the effect of the patient's symptoms on work/school, social life, and family/home responsibilities. For each of the three items, scores range from 0 through 10. The number most representative of how much each area was disrupted by symptoms is marked along the line from 0 = not at all, to 10 = extremely. For the work/school item, no response was to be entered if the patient did not work or go to school for reasons unrelated to the disorder and a response therefore not being applicable. The Mean SDS Score will be calculated over the three item scores. All three item scores need to be available with the exception of the work/school item score when this item is not applicable.
| Units on a scale | Brexpiprazole 2 mg/Day + ADT | Double-blind Placebo + ADT |
|---|---|---|
| Item: Work/School: Week 11 | -0.70 ± 0.21 | -0.42 ± 0.22 |
| Item: Work/School: Week 14 | -1.09 ± 0.22 | -0.90 ± 0.22 |
| Item: Social life: Week 11 | -1.17 ± 0.17 | -0.67 ± 0.17 |
| Item: Social life: Week 14 | -1.54 ± 0.19 | -1.04 ± 0.18 |
| Item: Family life: Week 11 | -1.06 ± 0.18 | -0.43 ± 0.18 |
| Item: Family life: Week 14 | -1.33 ± 0.19 | -0.73 ± 0.19 |
The SDS is a self-rated instrument used to measure the effect of the patient's symptoms on work/school, social life, and family/home responsibilities. For each of the three items, scores range from 0 through 10. The number most representative of how much each area was disrupted by symptoms is marked along the line from 0 = not at all, to 10 = extremely. For the work/school item, no response was to be entered if the patient did not work or go to school for reasons unrelated to the disorder and a response therefore not being applicable. The Mean SDS Score will be calculated over the three item scores. All three item scores need to be available with the exception of the work/school item score when this item is not applicable.
| Units on a scale | Brexpiprazole 2 mg/Day + ADT | Double-blind Placebo + ADT |
|---|---|---|
| Item: Work/School: Week 11 | -0.76 ± 0.22 | -0.58 ± 0.22 |
| Item: Work/School: Week 14 | -1.11 ± 0.23 | -0.96 ± 0.23 |
| Item: Social life: Week 11 | -1.18 ± 0.18 | -0.69 ± 0.18 |
| Item: Social life: Week 14 | -1.57 ± 0.19 | -1.02 ± 0.19 |
| Item: Family life: Week 11 | -0.99 ± 0.19 | -0.43 ± 0.18 |
| Item: Family life: Week 14 | -0.43 ± 0.18 | -0.70 ± 0.19 |
The HAM-D (17-Item) consists of 17 items. Eight items are rated on a 0 to 2 scale (items 4, 5, 6, 12, 13, 14, 16 and 17), while nine items (items 1, 2, 3, 7, 8, 9, 10, 11, and 15) are rated on a 0 to 4 scale (twice the weight of the other items). For all of these items, 0 is the "best" rating and the highest score (2 or 4) is the "worst" rating. The sum of the scores from the first 17 items; 0-7 =Normal; 8-13 =mild depression; 14-18 =moderate depression; 19-22 =severe depression; ≥23 =very severe depression. The total score ranges from 0 to 52, with higher score indicating worse depressive symptoms.
| Units on a scale | Brexpiprazole 2 mg/Day + ADT | Double-blind Placebo + ADT |
|---|---|---|
| Change From Baseline (End of Phase A [Week 8]) to Week 14 in Hamilton Depression (HAM-D) Rating Scale Total Score for the Efficacy Sample. | -5.89 ± 0.48 | -3.55 ± 0.47 |
The HAM-D (17-Item) consists of 17 items. Eight items are rated on a 0 to 2 scale (items 4, 5, 6, 12, 13, 14, 16 and 17), while nine items (items 1, 2, 3, 7, 8, 9, 10, 11, and 15) are rated on a 0 to 4 scale (twice the weight of the other items). For all of these items, 0 is the "best" rating and the highest score (2 or 4) is the "worst" rating. The sum of the scores from the first 17 items; 0-7 =Normal; 8-13 =mild depression; 14-18 =moderate depression; 19-22 =severe depression; ≥23 =very severe depression. The total score ranges from 0 to 52, with higher score indicating worse depressive symptoms.
| Units on a scale | Brexpiprazole 2 mg/Day + ADT | Double-blind Placebo + ADT |
|---|---|---|
| Change From Baseline (End of Phase A [Week 8]) to Week 14 in HAM-D Rating Scale Total Score for the Efficacy Sample Per the Final Protocol. | -5.89 ± 0.51 | -3.59 ± 0.49 |
The HAM-A is utilized for the evaluation of anxiety symptoms. The HAM-A consists of 14 items. Each item is rated on a 0 to 4 scale. For all of these items, 0 is the "best" rating and 4 is the "worst" rating. If no item scores are missing, then the HAM-A total score is the sum of all 14 item scores. The possible total scores are from 0 to 56, with higher scores indicating worse anxiety symptoms.
| Units on a scale | Brexpiprazole 2 mg/Day + ADT | Double-blind Placebo + ADT |
|---|---|---|
| Change From Baseline (End of Phase A [Week 8]) to Week 14 in Hamilton Anxiety (HAM-A) Rating Scale Total Score for the Efficacy Sample | -3.94 ± 0.43 | -2.77 ± 0.42 |
The HAM-A is utilized for the evaluation of anxiety symptoms. The HAM-A consists of 14 items. Each item is rated on a 0 to 4 scale. For all of these items, 0 is the "best" rating and 4 is the "worst" rating. If no item scores are missing, then the HAM-A total score is the sum of all 14 item scores. The possible total scores are from 0 to 56, with higher scores indicating worse anxiety symptoms.
| Units on a scale | Brexpiprazole 2 mg/Day + ADT | Double-blind Placebo + ADT |
|---|---|---|
| Change From Baseline (End of Phase A [Week 8]) to Week 14 in HAM-A Rating Scale Total Score for the Efficacy Sample Per the Final Protocol. | -3.79 ± 0.45 | -2.70 ± 0.43 |
The MADRS response was defined as \>/=50% reduction in MADRS total score from end of Phase A (Week 8).
| Percentage of participants | Brexpiprazole 2 mg/Day + ADT | Double-blind Placebo + ADT |
|---|---|---|
| Percentage of Participants With MADRS Response at Week 14 Relative to Baseline (End of Phase A [Week 8]) for the Efficacy Sample. | 23.5 | 14.7 |
The MADRS response was defined as \>/=50% reduction in MADRS total score from end of Phase A (Week 8).
| Percentage of participants | Brexpiprazole 2 mg/Day + ADT | Double-blind Placebo + ADT |
|---|---|---|
| Percentage of Participants With MADRS Response at Week 14 Relative to Baseline (End of Phase A [Week 8]) for the Efficacy Sample Per the Final Protocol. | 23.4 | 15.7 |
MADRS remission was defined as \</=10 and \>/=50% reduction in MADRS total score from end of Phase A (Week 8).
| Percentage of participants | Brexpiprazole 2 mg/Day + ADT | Double-blind Placebo + ADT |
|---|---|---|
| Percentage of Participants With MADRS Remission at Week 14 Relative to Baseline (End of Phase A [Week 8]) for the Efficacy Sample. | 14.4 | 8.38 |
MADRS remission was defined as \</=10 and \>/=50% reduction in MADRS total score from end of Phase A (Week 8).
| Percentage of participants | Brexpiprazole 2 mg/Day + ADT | Double-blind Placebo + ADT |
|---|---|---|
| Percentage of Participants With MADRS Remission at Week 14 Relative to Baseline (End of Phase A [Week 8]) for the Efficacy Sample Per the Final Protocol. | 14.9 | 8.99 |
CGI-I response was defined as a CGI-I score of 1 (very much improved) or 2 (much improved).
| Percentage of participants | Brexpiprazole 2 mg/Day + ADT | Double-blind Placebo + ADT |
|---|---|---|
| Percentage of Participants With CGI-I Scale Response Rate at Week 14 Relative to Baseline (End of Phase A [Week 8]) for the Efficacy Sample. | 44.4 | 27.7 |
CGI-I response was defined as a CGI-I score of 1 (very much improved) or 2 (much improved).
| Percentage of participants | Brexpiprazole 2 mg/Day + ADT | Double-blind Placebo + ADT |
|---|---|---|
| Percentage of Participants With CGI-I Scale Response Rate at Week 14 Relative to Baseline (End of Phase A [Week 8]) for the Efficacy Sample Per the Final Protocol. | 43.4 | 26.4 |
Collected over Adverse Events with an onset date on or after the start of double-blind treatment and occurring up to 30 days after the last day of double-blind treatment were included.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Brexpiprazole 2 mg/Day + ADT | — | 2/188 (1.1%) | 37/188 (19.7%) |
| Double-blind Placebo + ADT | — | 2/191 (1%) | 27/191 (14.1%) |
| Event | Brexpiprazole 2 mg/Day + ADT | Double-blind Placebo + ADT |
|---|---|---|
| Abdominal PainGastrointestinal disorders | 1/188 | 0/191 |
| Comminuted FractureInjury, poisoning and procedural complications | 1/188 | 0/191 |
| SyncopeNervous system disorders | 1/188 | 0/191 |
| Atrial FibrillationCardiac disorders | 0/188 | 1/191 |
| PneumoniaInfections and infestations | 0/188 | 1/191 |
| Event | Brexpiprazole 2 mg/Day + ADT | Double-blind Placebo + ADT |
|---|---|---|
| Weight increasedInvestigations | 15/188 | 6/191 |
| AkathisiaNervous system disorders | 14/188 | 2/191 |
| Upper resporatory tract infectionInfections and infestations | 6/188 | 12/191 |
| DiarrhoeaGastrointestinal disorders | 5/188 | 10/191 |
Randomized sample were used. Randomized sample comprises all who were randomized in Phase B.
| Age, Continuous(Years) | Brexpiprazole 2 mg/Day + ADT | Double-blind Placebo + ADT | Total |
|---|---|---|---|
| Mean | 44.1 ± 11.6 | 45.2 ± 11.3 | 44.6 ± 11.5 |
| Sex: Female, Male(Participants) | Brexpiprazole 2 mg/Day + ADT | Double-blind Placebo + ADT | Total |
|---|---|---|---|
| Female | 130 | 137 | 267 |
| Male | 58 | 54 | 112 |
The record gives a start of Jul 2011, a primary completion of May 2013 and a completion of Jun 2013. It does not say whether these dates are actual or estimated.
Results were first posted in Nov 2015, 2 years 6 months after primary completion. A results delay was requested in May 2014.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Oct 2015. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Brexpiprazole · Antiandrogens
Otsuka Pharmaceutical Development & Commercialization, Inc. →